An Open Label Positron Emission Tomography Study in Healthy Male Subjects to Investigate Brain Dopamine D3 Receptor Occupancy, Pharmacokinetics and Safety of Single Oral Doses of GSK618334, Using 11C-PHNO as PET Ligand.
Phase of Trial: Phase I
Latest Information Update: 10 Jul 2017
At a glance
- Drugs GSK 618334 (Primary)
- Indications Drug abuse
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 11 Jul 2009 Actual end date (Jun 2009) added as reported by ClinicalTrials.gov.
- 11 Jul 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 28 Jan 2009 New trial record